比较伊立替康加卡培他滨或加醛氢叶酸联合西妥昔单抗治疗转移性左半结肠癌的临床疗效及安全性  

Comparison of the efficacy and safety of irinotecan + capecitabine or irinotecan + leucovorin regimen in combination with cetuximab in treating metastatic left colon cancer

作　　者：邓伟锋 DENG Weifeng(Department of Oncology,Suzhou Yongding Hospital,Suzhou 215200,China)

机构地区：[1]苏州永鼎医院肿瘤内科,苏州215200

出　　处：《中国研究型医院》2021年第5期47-50,共4页Chinese Research Hospitals

摘　　要：目的探讨伊立替康+卡培他滨(mXELIRI)方案、伊立替康+醛氢叶酸(mFOLFIRI)方案分别联合西妥昔单抗治疗转移性左半结肠癌的临床疗效及安全性。方法前瞻性选取2018年1月至2020年1月于我院治疗的60例转移性左半结肠癌患者为研究对象。根据抽签法将患者分为对照组和试验组,每组30例,对照组给予mFOLFIRI方案联合西妥昔单抗治疗,试验组接受mXELIRI方案联合西妥昔单抗治疗,采用χ^(2)检验比较两组的疾病控制率、缓解率及手足综合征、腹泻、骨髓抑制不良反应的发生情况。结果试验组的疾病缓解率、控制率(76.67%、93.33%)分别明显高于对照组(50.00%、70.00%),差异有统计学意义(χ^(2)值分别为4.593、5.455,P值均<0.05);试验组的不良反应发生率(30.00%)与对照组(36.67%)比较,差异无统计学意义(χ^(2)=0.300,P> 0.05)。结论采用mXELIRI方案联合西妥昔单抗较mFOLFIRI方案联合西妥昔单抗治疗转移性左半肠癌的临床效果突出,值得推广。Objective To explore the clinical efficacy and safety of irinotecan + capecitabine(m XELIRI) regimen and irinotecan + leucovorin(mFOLFIRI) regimen in combination with cetuximab in treating metastatic left colon cancer, respectively. Methods Sixty patients were prospectively selected for the study. They had metastatic left colon cancer. These patients were treated at our hospital from January 2018 to January 2020. The patients were divided into the control group and experimental group by lots.There were 30 cases in each group. The control group was treated with an mFOLFIRI regimen combined with cetuximab. The experimental group was treated with an mXELIRI regimen combined with cetuximab.χ^(2) test was used to compare the disease control rate, remission rate, and the incidence of adverse effects such as hand-foot syndrome, diarrhea, and bone marrow suppression in the two groups. Results The remission rate and control rate in the experimental group(76.67% and 93.33%) were significantly higher than those in the control group(50.00% and 70.00%) respectively. The differences were statistically significant(χ^(2)=4.593,5.455;both P < 0.05);There was no significant difference in the incidence of adverse reactions between the experimental group(30.00%) and the control group(36.67%)(χ^(2)=0.300, P > 0.05). Conclusion The clinical effect of the mXELIRI regimen combined with cetuximab is better than the mFOLFIRI regimen combined with cetuximab in treating metastatic left colon cancer is outstanding and worth promoting.

关 键 词：结直肠肿瘤 肿瘤转移 西妥昔单抗 靶向治疗 药物疗法 联合 

分 类 号：R735.35[医药卫生—肿瘤]